GE aligns with Janssen for Alzheimer's disease detection
GE Healthcare has collaborated with Janssen Pharmaceutica in Beerse, Belgium, to identify a biosignature related to Alzheimer's disease.

This research effort will combine expertise in data integration, informatics, genomics and imaging and the goal will be to find a biosignature that may enable the detection of Alzheimer's disease before the onset of clinical symptoms, said GE.  

GE added that phase 3 trials are underway for GE’s amyloid PET imaging compound Flutemetamol.